Fu XP. Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management. World J Clin Cases 2025; 13(14): 100262 [DOI: 10.12998/wjcc.v13.i14.100262]
Corresponding Author of This Article
Xiao-Peng Fu, College of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, No. 1 Qiuyang Road, Fuzhou 350122, Fujian Province, China. 1220105011@fjtcm.edu.cn
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 16, 2025; 13(14): 100262 Published online May 16, 2025. doi: 10.12998/wjcc.v13.i14.100262
Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management
Xiao-Peng Fu
Xiao-Peng Fu, College of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, Fujian Province, China
Author contributions: Fu XP was responsible for the design of the study, writing the manuscript, revising the manuscript, and approving the final version; Fu XP agrees to be accountable for all aspects of the work.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Peng Fu, College of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, No. 1 Qiuyang Road, Fuzhou 350122, Fujian Province, China. 1220105011@fjtcm.edu.cn
Received: August 11, 2024 Revised: December 22, 2024 Accepted: December 30, 2024 Published online: May 16, 2025 Processing time: 156 Days and 11.4 Hours
Abstract
The study by Lin et al delves into the clinical impact of dapagliflozin, a representative sodium-glucose cotransporter 2 (SGLT2) inhibitor, on chronic heart failure complicated by hyperuricemia. This investigation highlights dapagliflozin’s efficacy in lowering serum uric acid levels, enhancing cardiac function, and reducing cardiovascular events. This work not only provides a comprehensive analysis of dapagliflozin’s sustained benefits in these patients but also introduces novel insights for managing chronic heart failure exacerbated by elevated uric acid. Furthermore, this review examines the potential role of SGLT2 inhibitor in the context of gout, evaluating its mechanisms and clinical application prospects in the management of hyperuricemia, thereby further enriching the medical community’s understanding of SGLT2 inhibitor.
Core Tip: This article explores the dual benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in managing hyperuricemia and gout, particularly in patients with type 2 diabetes and cardiovascular complications. By highlighting the ability of SGLT2 inhibitors to lower uric acid levels and reduce the risk of gout flare-ups, this article provides insights into their potential as a comprehensive treatment option. The review also emphasizes the importance of understanding the underlying mechanisms, offering a new perspective on optimizing the clinical application of SGLT2 inhibitors in high-risk patients.
